LUPRON IS FIRST ABBOTT-TAKEDA PRODUCT TO REACH U.S. MARKET; FDA APPROVES SYNTHETIC LHRH ANALOG; WAS TREATED AS 1-A BREAKTHROUGH FOR PROSTATE CANCER

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".